The risk of autoimmunity associated with tumor immunotherapy

In summary, tumor vaccination via the targeting of self-antigens expressed in tumor cells can be achieved without undue autoimmune pathology, largely due to an apparent difference between the requirements for inducing tumor regression and autoimmune pathology. Such treatments are, however, not without associated risks or the need for compromises and will require well thought-out choices to be made on a case-by-case basis.